Advanced search
Publication Cover
Renal Failure Volume 42, 2020 - Issue 1
Submit an article Journal homepage
2,762
Views
11
CrossRef citations to date
0
Altmetric
Clinical Study

The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients

Susan L. Murraya Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, Ireland;b Department of Medicine, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence[email protected]
View further author information
,
Fergus E. Dalya Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, IrelandView further author information
,
Patrick O’Kellya Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, IrelandView further author information
,
Eamonn O’Learyc National Cancer Registry Ireland, Cork Airport Business Park, Cork, IrelandView further author information
,
Sandra Deadyc National Cancer Registry Ireland, Cork Airport Business Park, Cork, IrelandView further author information
,
James P. O’Neilld Department of Otolaryngology, Head & Neck Surgery, Beaumont Hospital, and Royal College of Surgeons, Ireland, IrelandView further author information
,
Alexander Dudleye Hepatology & Liver Transplant Department, St Vincent’s University Hospital, Dublin, IrelandView further author information
,
Nicholas R. Rutledgee Hepatology & Liver Transplant Department, St Vincent’s University Hospital, Dublin, IrelandView further author information
,
Aiden McCormicke Hepatology & Liver Transplant Department, St Vincent’s University Hospital, Dublin, IrelandView further author information
,
Diarmuid D. Houlihane Hepatology & Liver Transplant Department, St Vincent’s University Hospital, Dublin, IrelandView further author information
,
Yvonne Williamsa Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, IrelandView further author information
,
Patrick G. Morrisf Department of Oncology, Beaumont Hospital, Dublin, IrelandView further author information
,
Siona Ni Raghallaighg Department of Dermatology, Beaumont Hospital, Dublin, IrelandView further author information
,
Fergal J. Moloneyh Department of Dermatology, Mater Misericordia University Hospital University College, Dublin, IrelandView further author information
,
Donal J. Sextona Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, IrelandView further author information
&
Peter J. Conlona Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, Ireland;b Department of Medicine, Royal College of Surgeons in Ireland, Dublin, IrelandView further author information
 show all
Pages 607-612 | Received 29 Nov 2019, Accepted 28 May 2020, Published online: 01 Jul 2020

References

  • Schnuelle P, Lorenz D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998;9(11):2135–2141.
  • Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–1901.
  • Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–1691.
  • Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154(3):498–504.
  • Sexton DJ, O’Kelly P, O’Leary E, et al. Variation in nonmelanoma skin cancer incidence by treatment modality among patients receiving multiple kidney transplants. JAMA Dermatol. 2019;155(5):594.
  • Krynitz B, Edgren G, Lindelöf B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-a Swedish population-based study. Int J Cancer. 2013;132(6):1429–1438.
  • Wisgerhof HC, Edelbroek JRJ, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation. 2010;89(10):1231–1238.
  • Lott DDG, Manz R, Koch C, et al. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation. 2010;90(6):683–687.
  • Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005;125(5):1020–1025.
  • Geissler EK, Briggs J, Euvrard S, et al. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res. 2015;4:1–1.
  • McQuillan RF, O'Seaghdha CM, Bagatto A, et al. The effect of switching from calcineurin inhibitor to sirolimus on the incidence of skin cancers in kidney transplant recipients. J Eur Acad Dermatol Venereol. 2009;23(3):330–331.
  • Alberú J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011;92(3):303–310.
  • Salgo R, Gossmann J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10(6):1385–1393.
  • Campbell SB, Walker R, Tai SS, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. J Transplant. 2012;1146:1146–1156.
  • Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev. 2006;(2):CD004290.
  • Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. Br Med J. 2014;349:6679–6679.
  • Karia PS, Azzi JR, Heher EC, et al. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer. JAMA Dermatol. 2016;152(5):533–540.
  • Cardinal H, Froidure A, Dandavino R, et al. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study. Transplant Proc. 2009;41(8):3308–3310.
  • Garrouste C, Kamar N, Guilbeau-Frugier C, et al. Long-term results of conversion from calcineurin inhibitors to sirolimus in 150 maintenance kidney transplant patients. Exp Clin Transplant. 2012;10(2):110–118.
  • Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296–303.
  • Pardo R, Colin E, Régulier E, et al. Inhibition of Calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci. 2006;26(5):1635–1645.
  • Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335–348.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.